Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider.
Alessia AlunnoAurélie NajmXavier MarietteGabriele de MarcoJenny EmmelLaura MasonDennis G McGonaglePedro M MachadoPublished in: RMD open (2021)
This new SLR confirms that some immunomodulators (tocilizumab and JAK inhibitors) have a role for treating severe and critical COVID-19. Although better evidence is available compared with the previous SLR, the need of RCT with combination therapy (glucocorticoids+anti-cytokines) versus monotherapy with glucocorticoids still remains alongside the need for standardisation of inclusion criteria and outcomes to ultimately improve the care and prognosis of affected people. This SLR informed the 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19.
Keyphrases
- combination therapy
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- healthcare
- rheumatoid arthritis
- palliative care
- early onset
- quality improvement
- randomized controlled trial
- clinical trial
- systemic lupus erythematosus
- metabolic syndrome
- insulin resistance
- open label
- smoking cessation
- affordable care act
- double blind